545 related articles for article (PubMed ID: 18538732)
41. Molecular findings in childhood leukemia in Brazil: high frequency of MLL-ENL Fusion/t(11;19) in infant leukemia.
Marques EA; Neves L; Fonseca TC; Lins MM; Pedrosa F; Lucena-Silva N
J Pediatr Hematol Oncol; 2011 Aug; 33(6):470-4. PubMed ID: 21436736
[TBL] [Abstract][Full Text] [Related]
42. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.
Jenkins CE; Shevchuk OO; Giambra V; Lam SH; Carboni JM; Gottardis MM; Holzenberger M; Pollak M; Humphries RK; Weng AP
Exp Hematol; 2012 Sep; 40(9):715-723.e6. PubMed ID: 22613471
[TBL] [Abstract][Full Text] [Related]
43. miR-101 suppresses the development of
Gonzales-Aloy E; Connerty P; Salik B; Liu B; Woo AJ; Haber M; Norris MD; Wang J; Wang JY
Haematologica; 2019 Jul; 104(7):e296-e299. PubMed ID: 30792205
[No Abstract] [Full Text] [Related]
44. MLL/AF-4 leukemic cells recruit new blood vessels but do not incorporate into capillaries in culture or in a NOD/SCID xenograft model.
Hu Z; Li XM; Jorgensen ML; Slayton WB
Leukemia; 2009 May; 23(5):990-3. PubMed ID: 19158831
[No Abstract] [Full Text] [Related]
45. Myeloid transformation by
Wesolowski R; Kowenz-Leutz E; Zimmermann K; Dörr D; Hofstätter M; Slany RK; Mildner A; Leutz A
Life Sci Alliance; 2021 Jan; 4(1):. PubMed ID: 33144337
[TBL] [Abstract][Full Text] [Related]
46. Installation of a cancer promoting WNT/SIX1 signaling axis by the oncofusion protein MLL-AF9.
Zhang LS; Kang X; Lu J; Zhang Y; Wu X; Wu G; Zheng J; Tuladhar R; Shi H; Wang Q; Morlock L; Yao H; Huang LJ; Maire P; Kim J; Williams N; Xu J; Chen C; Zhang CC; Lum L
EBioMedicine; 2019 Jan; 39():145-158. PubMed ID: 30528456
[TBL] [Abstract][Full Text] [Related]
47. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML.
Sheng Y; Yu C; Liu Y; Hu C; Ma R; Lu X; Ji P; Chen J; Mizukawa B; Huang Y; Licht JD; Qian Z
Nat Commun; 2020 Feb; 11(1):928. PubMed ID: 32066721
[TBL] [Abstract][Full Text] [Related]
48. HOXA9 is required for survival in human MLL-rearranged acute leukemias.
Faber J; Krivtsov AV; Stubbs MC; Wright R; Davis TN; van den Heuvel-Eibrink M; Zwaan CM; Kung AL; Armstrong SA
Blood; 2009 Mar; 113(11):2375-85. PubMed ID: 19056693
[TBL] [Abstract][Full Text] [Related]
49. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV; Armstrong SA; Hahn WC; Huntly BJ; Sykes SM; Milsom MD; Scholl C; Fröhling S
Blood; 2014 Jul; 124(1):13-23. PubMed ID: 24764564
[TBL] [Abstract][Full Text] [Related]
50. Integrated transcriptomic and epigenetic data analysis identifiesaberrant expression of genes in acute myeloid leukemia with MLL‑AF9 translocation.
Wang F; Li Z; Wang G; Tian X; Zhou J; Yu W; Fan Z; Dong L; Lu J; Xu J; Zhang W; Liang A
Mol Med Rep; 2020 Feb; 21(2):883-893. PubMed ID: 31789407
[TBL] [Abstract][Full Text] [Related]
51. miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia.
Malouf C; Antunes ETB; O'Dwyer M; Jakobczyk H; Sahm F; Landua SL; Anderson RA; Soufi A; Halsey C; Ottersbach K
Blood; 2021 Nov; 138(21):2066-2092. PubMed ID: 34111240
[TBL] [Abstract][Full Text] [Related]
52. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
53. Establishment of MLL/AF4 transgenic mice with the phenotype of lymphoblastic leukemia or lymphoma.
Tamai H; Inokuchi K
J Nippon Med Sch; 2013; 80(5):326-7. PubMed ID: 24189350
[No Abstract] [Full Text] [Related]
54. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.
Bursen A; Schwabe K; Rüster B; Henschler R; Ruthardt M; Dingermann T; Marschalek R
Blood; 2010 Apr; 115(17):3570-9. PubMed ID: 20194896
[TBL] [Abstract][Full Text] [Related]
55. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
56. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
57. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
58. Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia.
Zhang Y; Owens K; Hatem L; Glass CH; Karuppaiah K; Camargo F; Perkins AS
Blood; 2013 Oct; 122(16):2888-92. PubMed ID: 24021671
[TBL] [Abstract][Full Text] [Related]
59. Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
Sontakke P; Carretta M; Jaques J; Brouwers-Vos AZ; Lubbers-Aalders L; Yuan H; de Bruijn JD; Martens AC; Vellenga E; Groen RW; Schuringa JJ
Leukemia; 2016 Oct; 30(10):2064-2073. PubMed ID: 27125308
[TBL] [Abstract][Full Text] [Related]
60. Bahcc1 is critical for the aberrant epigenetic program in a mouse model of MLL-ENL-mediated leukemia.
Nakamura A; Masuya M; Shinmei M; Tawara I; Nosaka T; Ono R
Blood Adv; 2024 May; 8(9):2193-2206. PubMed ID: 38452334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]